Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "injectable"

390 News Found

Caplin gets USFDA approval for Sumatriptan
News | July 15, 2021

Caplin gets USFDA approval for Sumatriptan

Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache


Honeywell launches solutions to prevent counterfeit pharma products
News | June 23, 2021

Honeywell launches solutions to prevent counterfeit pharma products

The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers


Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
Drug Approval | May 31, 2021

Cadila Healthcare’s margin supported by lower R&D : ICICI Securities

India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact


Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
News | May 31, 2021

Multiple catalysts ahead for Cadila Healthcare: HDFC Securities

Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.


Glenmark receives ANDA approval for Icatibant Injection
News | May 25, 2021

Glenmark receives ANDA approval for Icatibant Injection

This marks Glenmark's first synthetic decapeptide injectable approval


Caplin Steriles gets USFDA approval
News | April 23, 2021

Caplin Steriles gets USFDA approval

The injection comes in multiple formats


Piramal Enterprises cashing in on opportunities: ICICI Securities
News | March 02, 2021

Piramal Enterprises cashing in on opportunities: ICICI Securities

PEL will explore the PLI scheme and apply if its beneficial.


Zydus completes enrolment for two Phase Ill trials of Desidustat
News | February 08, 2021

Zydus completes enrolment for two Phase Ill trials of Desidustat

The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business